SCHEMBL710142

SCHEMBL710142

NC(=O)N(S)c1ccc(S(=O)(=O)Nc2nccs2)cn1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
LMNA P02545 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
KDM4E B2RXH2 1/20 0.54
CYP2C9 P11712 1/20 0.54
EDNRA P25101 1/20 0.54
SLC6A4 P31645 1/20 0.54
ADRA1A P35348 1/20 0.54
PRMT6 Q96LA8 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.51
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
CYP1A2 P05177 1/20 0.50
PKM P14618 2/20 0.48
TSHR P16473 1/20 0.47
BRAF P15056 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
SYK P43405 1/20 0.46
SCN3A Q9NY46 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712101 0.76 ALDH1A1 (0.71) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL3278437 0.75 ALDH1A1 (0.69) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL710141 0.74 ALDH1A1 (0.56) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL12383540 0.73 ALDH1A1 (0.62) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL713015 0.73 LMNA (0.71) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL713273 0.72 SCN9A (0.51) SCN3A
Sulfathiazole SCHEMBL94165 0.71 ALDH1A1 (1.00) ALDH1A1LMNATDP1KDM4ECYP2C9
Sulfathiazole SCHEMBL30130508 0.71 ALDH1A1 (1.00) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL1650814 0.71 ALDH1A1 (0.72) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL8511604 0.71 ALDH1A1 (0.59) ALDH1A1LMNATDP1KDM4ECYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A ALDH1A1 3333/4885LMNA 2921/4885TDP1 4343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.